SGAS 613, Conj. E Bloco A , Sala 06 - Subsolo , Asa Sul - Brasília/DF, CEP: 70.200-730
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Luciana Campos
Tauã Velloso
Rodrigo Melo
Felipe Barros
Licia Stanzani
Diana Rocha de Sá
Fernanda Pereira
Arthur Sousa
Eduardo Vasconcellos
Felipe von Glehn
Miriam Amaral Eneas
Beatriz Vilar
Victória Oliveira
Manuela Fragomeni
Andréia Naomi Madoz Kaya
João Victor de Souza Cardoso
Vanessa Santos
Open studies
Alzheimer disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) - ADEPT-4 - Karuna Therapeutics
Cardiovascular disease
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company
Chronic obstructive pulmonary disease
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) - EMBARK - AstraZeneca
Elevated Lipoprotein A
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company
Lupus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus - AMETHYST - Biogen
Multiple sclerosis
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis - FREVIVA - Sanofi
Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis - FREXALT - Sanofi
Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company
Renal disease
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company
Urticaria
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria - EMBARQ-CSU1 - Celldex Therapeutics
